Skip to content
HowShorted

KalVista Pharmaceuticals, Inc. short interest in 2020

In 2020, KalVista Pharmaceuticals, Inc.'s disclosed short interest ran from 4.07% of shares outstanding on 15 Jan 2020 to 2.13% on 31 Dec 2020, a change of -1.94 percentage points. The year's high was 4.07% on 15 Jan 2020 and its low 1.24% on 30 Oct 2020, averaging 2.25% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.17 days on 31 Jan 2020. Full history: KalVista Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for KalVista Pharmaceuticals, Inc. in 2020

2020 in figures

Start of year
4.07% (15 Jan 2020)
End of year
2.13% (31 Dec 2020)
Change
-1.94 pp
High
4.07% (15 Jan 2020)
Low
1.24% (30 Oct 2020)
Average
2.25%
Highest days to cover
8.17 (31 Jan 2020)
SEC filings marked
8

Every report in 2020

KalVista Pharmaceuticals, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 20204.07%5.60
31 Jan 20203.93%8.17
14 Feb 20203.46%6.75
28 Feb 20203.49%6.72
13 Mar 20203.40%3.0610-Q filed, results (8-K)
31 Mar 20202.25%2.32
15 Apr 20202.01%2.49
30 Apr 20201.94%4.52
15 May 20201.89%3.90
29 May 20201.91%2.96
15 Jun 20201.77%5.08
30 Jun 20202.20%1.42
15 Jul 20202.41%3.8810-K filed, results (8-K)
31 Jul 20202.20%4.69
14 Aug 20202.00%3.95
31 Aug 20201.79%7.66
15 Sep 20201.66%7.7410-Q filed, results (8-K)
30 Sep 20201.38%5.91
15 Oct 20201.42%5.55
30 Oct 20201.24%1.68
13 Nov 20201.83%2.43
30 Nov 20201.90%4.53
15 Dec 20201.67%4.0510-Q filed, results (8-K)
31 Dec 20202.13%2.82

See also: KalVista Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.